In 2022 eviQ and CINSW developed and published the International Consensus Guideline for Anticancer Drug Dosing in Kidney Dysfunction (ADDIKD). eviQ protocols and content began to be updated with the ADDIKD guideline recommendations in 2023.
This FAQ provides guidance on common questions regarding assessing kidney function, eviQ calculators, changes to eviQ protocols and content, and dosing of carboplatin.
Title